Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Rohto to Introduce Sliming Supplement from Italy
February 19, 2001
- ABBREVIATION OF THE WEEK
February 12, 2001
- Korosho Calls For National Debates on Healthcare Reform
February 12, 2001
- AstraZeneca Aiming at Entering Top 10 by End of 2005: Mr Angelici
February 12, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -1-
February 12, 2001
- Rush of New Drug Launches from Foreign Companies Continues
February 12, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -2-
February 12, 2001
- Pharmacists Should Serve as Risk Managers: SJP Seminar
February 12, 2001
- Taisho Licenses in Antiobesity Agents from Arena
February 12, 2001
- WORLD NEWS IN BRIEF
February 12, 2001
- REGULATORY NEWS IN BRIEF
February 12, 2001
- Asahi Chemical, Janssen-Kyowa to Make Utmost Efforts to Expand Japan's 1st SNRI Market
February 12, 2001
- NDA Review System Should Be Reformed as Part of Administrative Reform: New ELD Director
February 12, 2001
- Demographic Estimates for 2000 Show More Births: Koseisho
February 12, 2001
- EMA Proposes Measures to Encourage Use of Generics
February 12, 2001
- Korosho to Issue Notification in May to Introduce CTD
February 12, 2001
- Record-low Population Growth Rate Marked: Nat'l Census
February 12, 2001
- Senshu Yakuhin Restarts Business as Subsidiary of Kuraya Sanseido
February 12, 2001
- Kemporen Calls For Elimination of Financial Contribution to Elderly Healthcare
February 12, 2001
- 39 Monodrugs, 2 Combination Drugs Designated: Quality Reevaluation
February 12, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…